Progress with interferon in CML--results of the MRC UK CML III study.
527 patients with CML were entered into the multicentre randomised MRC CML III study comparing IFN-alpha n1 to standard chemotherapy, either busulphan or hydroxyurea. Haematologic response to IFN as assessed by the level of control of the WCC predicted cytogenetic response to IFN. Cytogenetic respon...
Main Authors: | Shepherd, P, Richards, S, Allan, N |
---|---|
Format: | Conference item |
Published: |
1996
|
Similar Items
-
INTERFERON-ALPHA(IFN-ALPHA) PROLONGS SURVIVAL FOR PATIENTS WITH CML IN CHRONIC PHASE - PRELIMINARY-RESULTS OF THE UK MRC RANDOMIZED MULTICENTER TRIAL
by: Allan, N, et al.
Published: (1994) -
A randomised comparison of low or high dose IFN-alpha in newly diagnosed CML patients shows no difference in major cytogenetic response rate or survival between the two groups - Results of MRC CML V and HOVON 20 trials.
by: Shepherd, P, et al.
Published: (2001) -
Thioguanine used in maintenance therapy of chronic myeloid leukaemia causes non-cirrhotic portal hypertension. Results from MRC CML. II. Trial comparing busulphan with busulphan and thioguanine.
by: Shepherd, P, et al.
Published: (1991) -
P706: ASCIMINIB USE IN CML: THE UK EXPERIENCE
by: A. Innes, et al.
Published: (2022-06-01) -
International CML forum
by: A. G. Turkina
Published: (2022-11-01)